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Autoimmune diabetes is characterized by inflamma-
tory infiltration; however, the initiating events are
poorly understood. We found that the islets of Lang-
erhans in young nonobese diabetic (NOD) mice
contained two antigen-presenting cell (APC) popula-
tions: a major macrophage and a minor CD103+ den-
dritic cell (DC) population. By 4 weeks of age, CD4+
T cells entered islets coincident with an increase in
CD103+ DCs. In order to examine the role of the
CD103+ DCs in diabetes, we examined Batf3-defi-
cient NOD mice that lacked the CD103+ DCs in islets
and pancreatic lymph nodes. This led to a lack of au-
toreactive T cells in islets and, importantly, no inci-
dence of diabetes. Additional examination revealed
that presentation of major histocompatibility com-
plex (MHC) class I epitopes in the pancreatic lymph
nodes was absent with a partial impairment of MHC
class II presentation. Altogether, this study reveals
that CD103+ DCs are essential for autoimmune dia-
betes development.
INTRODUCTION
The progression of type 1 diabetes in nonobese diabetic (NOD)
mice has been extensively investigated using a number of
different approaches, with an emphasis on the involvement of
different T cell subsets, effector molecules, and cytokines (An-
derson and Bluestone, 2005). However, the role of specific anti-
gen-presenting cell (APC) subsets, particularly as it concerns the
critical initial stages of diabetes, has been examined in limited
ways. Normal islets of Langerhans in all species, including the
prediabetic NOD mouse strain, contain APCs that are required
for normal islet function (Calderon and Unanue, 2012). These
APCs take up secretory granules and are instrumental in the pre-
sentation of insulin peptides, a major antigenic determinant in
NOD diabetogenesis (Mohan et al., 2010, 2013). Presentation
of diabetogenic antigens in the draining pancreatic lymph nodes
(pLN) is also central to diabetes development, strongly pointing
to a translocation of some of the islet APCs into them (Gagneraultet al., 2002; Ho¨glund et al., 1999; Kurts et al., 1997; Levisetti
et al., 2004; Zhang et al., 2002).
Diverse findings point out that CD4+ T cell responses are
a major component of the islet autoreactivity, particularly for
insulin-derived peptides (Brezar et al., 2011; Daniel et al., 1995;
Nakayama et al., 2005; Unanue, 2014; Wegmann et al., 1994;
Zhang et al., 2008). These findings agree with the dependence
on alleles of class II major histocompatibility complex (MHC)
genes for disease susceptibility in both mouse and human type
1 diabetes. Although there is a strong influence of class II genes
in both mice and humans, there is also a strong component
of reactivity to peptides presented by class I MHC molecules
for disease development. Cooperativity between diabetogenic
CD4+ and CD8+ T cells has been extensively studied in the
NOD mouse model (Bendelac et al., 1987; Christianson et al.,
1993; de Jersey et al., 2007; Krishnamurthy et al., 2006, 2008;
Miller et al., 1988; Serreze et al., 2004).
In the mouse, the Batf3 transcription factor regulates the dif-
ferentiation of a subset of conventional dendritic cells (cDCs)
that comprises the CD8a+ DC in secondary lymphoid organs
and the tissue resident CD103+ DC (Edelson et al., 2010; Hildner
et al., 2008; Mashayekhi et al., 2011). This subset of cDCs is
important in the presentation of class I-MHC-bound peptides
derived from microbes, dead cells, and cell-bound antigens.
This subset appears to be less involved in CD4+ T cell responses.
Reports examining mice with ablation of the Batf3 gene are
enlightening in showing the role of the Batf3-dependent CD8a+
and CD103+ DC subset in immune responses to viruses, tumors,
and parasites (Belz et al., 2004, 2005; den Haan et al., 2000;
Liu and Nussenzweig, 2010; Pooley et al., 2001; Satpathy
et al., 2012). Previous studies show that the CD8a+ and
CD103+ DC subsets correspond to the same lineage of DCs
(Edelson et al., 2010).
We have evaluated here the effects of a Batf3 null mutation
on the autoimmune diabetes of the NODmouse. We first carried
out a comprehensive cellular and gene expression analysis of
the islet APCs of NOD mice, concluding that islets contained
a small set of CD103+ DC, together with a major component of
macrophages. In NODmice, therewas an increase in the number
of CD103+ DC in islets from the 4th to 12th week of age, coin-
ciding with the entrance of CD4+ T cells. This increase required
autoreactivity to insulin. Next, the absence of CD103+ DC
in NOD.Batf3/ mice changed the islet genetic profile to one
that resembled NOD.Rag1/ mice. The NOD.Batf3/ miceImmunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc. 657
Figure 1. Absence of Diabetes or Immunological Infiltrates in NOD.Batf3–/– Mice
(A) Diabetes incidence in female NOD (n = 24), NOD.Batf3/ (n = 24), and NOD.Batf3+/ (n = 8). See also Tables S1 and S2.
(B–D) Hematoxylin and eosin staining of (B) a 6-week-old female NOD islet, (C) a 6-week-old female NOD.Batf3/ islet, and (D) a 52-week-old female
NOD.Batf3/ islet. Scale bars represent 100 mm.
(E–G) Flow cytometric profiles of CD4+ and CD8+ T cells from NOD and NOD.Batf3/ (E) thymocytes and (F) splenocytes, respectively. Percentage of CD103+
and CD11blo to negative cells of (G) pLN and (H) mesenteric lymph nodes (gated on CD45+, CD11c+, MHC-II+).
(I) Percentage of DEC205+ (CD205) and CD8a+ cells of spleen (gated on CD45+, CD11c+, MHC-II+ cells). All flow cytometry plots are representative of two ormore
independent experiments.
See also Figure S1 and Tables S1 and S2.
Immunity
CD103+ DCs Control Development of Type 1 Diabeteslacked any evidence of autoreactivity, and diabetes was absent.
Therefore, a small subset of DC controls the development of dia-
betic autoimmunity.
RESULTS
Batf3-Deficient Mice Do Not Develop Diabetes
A 129S6.Batf3/ allele (Hildner et al., 2008) was backcrossed to
the NOD background by speed congenic approaches and
confirmed by microsatellite analysis (see Table S1 available on-
line). Single nucleotide polymorphism (SNP) analysis showed
that the NOD.Batf3/ mice contained all the insulin-dependent
diabetes (IDD) susceptibility alleles (Table S2). NOD.Batf3/
mice developed normally and were resistant to diabetes, and
no female mice developed disease. The cumulative incidence
of diabetes in our female NOD colony was 85% (Figure 1A).
NOD.Batf3+/mice showed a similar incidence of diabetes. His-
tological analysis of the NOD.Batf3/ mice at different ages
showed normal islet morphology (Figures 1B–1D). The islet in
Figure 1B was representative of the typical NOD profile with in-
traislet insulitis and peri-insulitis. The islets shown in Figures
1C–1D are representative of at least 20 NOD.Batf3/ pancreata658 Immunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc.examined. No lymphocyte infiltration was found in more than
400 islets examined among the various samples.
Examination of thymi, lymph nodes, and spleens from
NOD.Batf3/ showed normal percentages and ratios of CD4+
and CD8+ T cells, but the CD8a+ and CD103+ DCs were low to
undetectable (Figures 1E–1I; Figures S1D–S1F). These results
were comparable to those reported in 129S6.Batf3/ mice
(Edelson et al., 2010; Hildner et al., 2008). The percentage
of CD25+FoxP3+-positive T cells in the thymus, spleen, and
mesenteric lymph node was identical between NOD mice and
the NOD.Batf3/ mice (Figures S1A–S1C). In summary, the
only detectable immune cell defect in the NOD.Batf3/ mice
was the absence of the CD8a+ and CD103+ DC lineage.
NOD Islets of Langerhans Contain Macrophages and
Batf3-Dependent CD103+ DCs
In order to place the findings related above to the events taking
place in islets of NOD and NOD.Batf3/mice, it was necessary
to examine clean islet APC profiles (Li et al., 2009).
Islets from NOD contained two sets of APCs, the majority of
which (80%–90%) exhibited a macrophage profile when staining
surface molecules: high surface expression of F4/80, CD11b,
Figure 2. Two Sets of Myeloid Cells Are Identified in NOD Mice Islets
(A) Gating strategy for dispersed islets.
(B) F4/80+ and CD103+ staining of myeloid cells from 4-week-old and 8-week-old NOD (left) and NOD.Batf3/ (right) islets, as gated in (A).
(C and D) (C) CD11b+ and (D) MHC class II+ flow cytometry of F4/80+ (red), CD103+ (blue), or unstained (green) islet myeloid cells, as gated in (A). Representative
flow cytometry plots and cumulative data from two or more independent experiments are shown, with each experiment pooling two or more mouse islets per
sample.
(E–H) qRT-PCR was performed on sorted populations of islet cells. Islets represent large and granular CD45 cells. F4/80+ and CD103+ were gated as shown in
Figure S2. All qRT-PCR is represented relative to the expression of 18 s rRNA (DCt). All qRT-PCRs represent data from two biological replicates of 10–15 pooled
female NOD mouse islets, each performed in duplicate (error bars denote SD). All mice used for qRT-PCR were 10–12 weeks old.
See also Figure S2.
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CD103+ DCs Control Development of Type 1 Diabetesand CD11c, and age-dependent surface expression of I-Ag7
(Figures 2A–2D). These cells have been previously termed by
us and others as islet DCs (Calderon et al., 2008; Ginhoux
et al., 2009; Melli et al., 2009; Yin et al., 2012). However, a deeper
analysis shows that they are macrophages.
At 4 weeks of age, CD103+ DCs were found in small numbers,
ranging from 2% to 7% of the islet myeloid cells (CD45+,
CD11c+, MHC-II+) (Figure 2B). At this time, the percentage
of CD45+ cells in islets ranged from 1% to 3% (Figure 2A).
CD103+ DCs were CD11chi and expressed intermediate
amounts of CD11b and I-Ag7 but did not express F4/80 (Figures2B–2D). A small number of CD45+, CD11c+, MHC-II+, F4/80,
and CD103 cells were also found (Figure 2B).
To further characterize the two sets of APCs and endocrine
cells, quantitative RT-PCR (qRT-PCR) was performed on cells
isolated from 10- to 12-week-old mouse islets (Figures 2E–2H;
Figure S2). Expression of CD3e, CD19, and Ins1 was absent
from the myeloid populations, ensuring the purity of our sorted
populations (Figure 2E). Ins1 expression was solely found in
the islet cells, and Ptprc (CD45) was expressed in the myeloid
populations (Figure 2E). Both the F4/80+ and CD103+ cells ex-
pressed Batf3,Clec9a, and Itgax (CD11c) (Figure 2F). The sortedImmunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc. 659
Figure 3. Lymphocyte Infiltration Is Absent
in NOD.Batf3–/– Mice Islets
(A and B) Flow cytometric analysis of (A) CD103+
myeloid cells, gated as in Figure 2A, and (B)
CD3ε+ lymphocytes (gated on CD45+ cells) from
12-week-old NOD, NOD.Batf3/, NOD.B16A,
NOD.H4, and NOD.Rag1/ islets.
(C) Representative graph of data from (A) including
time course of NOD from 3 to 12 weeks of age.
(D) Representative graph of data from (B) including
NOD time course from 3 to 12 weeks of age.
Representative flow cytometry plots and cumula-
tive data from three or more independent experi-
ments are shown, with each experiment pooling
two or more mouse islets per sample (error bars
denote SD).
(E) Flow cytometry of islet lymphocyte and
myeloid cells from NOD, NOD.Batf3/, and
NOD.Batf3/ that received either NOD.Rag1/
or NOD.Batf3/ 3 Rag1/ bone marrow
23 weeks prior to being harvested.
See also Figure S3.
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CD103+ DCs Control Development of Type 1 DiabetesF4/80+ cells expressedmacrophage-characteristic genes (Gaut-
ier et al., 2012) Emr1 (F4/80), Itgam (Cd11b), Lyz2, and Mertk
while expressing low to undetectable DC-linked genes such as
Flt3, Itgae (CD103), Xcr1, and Zbtb46 (Figures 2G and 2H).
This expression profile contrasted with that of the CD103+ DC,
which displayed high expression of Zbtb46, Xcr1, and Flt3, low
expression of Itgam and Lyz2, and no detectable Emr1 (F4/80)
(Figures 2G and 2H; Crozat et al., 2011). Thus, the gene expres-
sion analysis, together with the surface markers, established the
identity of the two major intraislet myeloid cells as macrophages
and CD103+ DCs.
The CD103+ DCs were absent from islets of the NOD.Batf3/
mice that contained only the macrophages. The third set of
CD45+ cells (CD45+, CD11c+, MHC-II+, F4/80, and CD103)
shown in the lower left quadrant in Figure 2B was also absent660 Immunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc.or reduced. This cell may represent an
early stage of the CD103+ lineage in the
islets, but regardless, it was capable of
presenting antigen as shown below.
NOD Mouse Islets Develop a
Synchronous Increase in CD103+
DC and T Cells
Two major changes took place in islets of
NOD mice starting at 4–6 weeks of age.
First was an increase in the number of
CD103+ DCs peaking at 20% of the total
myeloid population by 8–12 weeks of
age (Figures 3A and 3C). Second, coin-
ciding with the increase in CD103+ DCs,
was the appearance of CD3ε+ T cells
within the islets (Figures 3B and 3D;
Carrero et al., 2013). No CD103+ myeloid
cells were found in the islets of
NOD.Batf3/ mice at any time (Figures
3A and 3C). Islets from NOD.Batf3/
mice did not contain intraislet T cells butonly the infrequent cells found as passenger leukocytes. The
percentage of passenger T cells in the islets of NOD.Batf3/
mice was the same found in all nondiabetic NOD congenic
strains (Figures 3B and 3D).
In order to determine the ability of the CD103+ DC to promote
T cell entry into islets, we utilized bone marrow chimeras
to reconstitute the missing CD8a+ and CD103+ DC lineage.
NOD.Batf3/ mice were irradiated at 3 weeks of age, and
NOD.Rag1/ bone marrow was injected to reconstitute the
missing DC lineage without introducing Batf3 sufficient lympho-
cytes. The missing CD103+ DCs were reconstituted in both the
islets and the pancreatic lymph nodes of the chimeras (Figure 3E;
Figure S3). Most notably, the islets of the chimeric mice dis-
played lymphocyte infiltration (Figure 3E). In contrast, control
NOD.Batf3/ 3 Rag1/ bone marrow was incapable of
Immunity
CD103+ DCs Control Development of Type 1 Diabetesreconstituting the CD103+ DCs or inducing lymphocyte infiltra-
tion (Figure 3E; Figure S3A). The pancreatic lymph node lympho-
cyte populations were unaffected by the bone marrow transfer
(Figure S3B). These data reinforced the necessity of the
CD103+ DCs for lymphocyte entry into islets and progression
of type 1 diabetes and established that the defect in diabetogen-
esis in NOD.Batf3/ mice was not intrinsic to the lymphocyte
population.
Nondiabetic NOD Congenic Strains Contain Low
Numbers of CD103+ DC
To examine the relationship between the presence of lympho-
cytes and the rise in CD103+ DCs between the 4- and 12-week
periods, we examined the NOD.Rag1/ mouse. The myeloid
(CD11c+, MHC-II+, CD45+) fraction of the islets were mostly
macrophages (95%) but also showed the low basal number
of CD103+ DC (5%). Their islets did not show the increase in
CD103+ DC that took place after 4 weeks of age in NOD mice
(Figures 3A and 3C).
In order to understand the correlation with CD103+ DC entry
into islets with T cell pathogenicity, we examined the NOD.H4
mouse, which has an intact lymphocyte compartment incapable
of driving autoimmune diabetes (Podolin et al., 1993). Its
genomic identity is derived from the NOD background except
that it contains the H-2h4 MHC haplotype. The islets showed a
low basal number of CD103+ DCs that never exceeded 2%–
5% of the islet myeloid cells (Figures 3A and 3C); leukocytes
within their islets mostly consisted of the F4/80+ macrophages
(Figure 3A). These small numbers of CD103+ DCs did not change
with age. As in other nondiabetogenic NOD congenic strains,
lymphocytes were not present in the islets of NOD.H4 mice at
12 weeks, and the number of passenger T cells was 4%–6%
of the very few islet CD45+ cells (Figures 3B and 3D).
The NOD.B16A mouse was developed to examine the impor-
tance of insulin recognition in NOD diabetes (Nakayama et al.,
2005). This strain lacks Ins1 and Ins2 gene expression and has
an Ins2 transgene with a mutation of tyrosine 16 to alanine within
the insulin beta chain. This mutation ablates T cell recognition
of a majority of insulin reactive T cells. NOD.B16A mice do not
develop diabetes. These findings support insulin autoreactivity
as the likely initiating event of the diabetic process (Brezar
et al., 2011; Jasinski and Eisenbarth, 2005; Unanue, 2014). We
have reported that the NOD.B16A strain lacks the intraislet lym-
phocytes that appear by the fourth to sixth week of life in NOD
mice.Moreover, insulin-reactive CD4+ T cells from a T cell recep-
tor transgenic mouse do not enter their islets (Mohan et al.,
2013). The islets of the NOD.B16A mice contained mostly mac-
rophages with the low basal percentage of CD103+ DCs. These
islets did not have the burst of CD103+ DCs in islets and only had
the small number of passenger lymphocytes (Figures 3A–3D).
These findings indicate that there is a low basal percentage of
CD103+ DCs within the islets of all NOD congenic strains. In
NOD, there is a rapid increase in the CD103+ DCs that coincides
with the infiltration of CD4+ T cells. According to previous
studies, the entrance of CD4+ T cells precedes that of CD8+
T cells (Carrero et al., 2013). Both this basal percentage and
the burst of CD103+ DCs were absent in mice lacking the Batf3
transcription factor. The increase above baseline of CD103+
DC was dependent on the presence of lymphocytes because itwas absent in NOD.Rag1/ mice. Moreover, the increase
in CD103+ DCs also required autoreactivity to insulin—e.g., it
was absent in the NOD.B16A mice that did not go on to develop
diabetes. Reconstitution of the CD8a+ and CD103+ lineage in the
NOD.Batf3/ mouse led to T cell and CD103+ DC entry into
islets and diabetes development. Thus, for the autoreactive
process to be activated, there is an absolute requirement of
both insulin-reactive T cells and CD103+ DCs.
The NOD.Batf3–/– Mice Display a Transcriptional
Signature Identical to theNondiabetic NOD.Rag1–/–Mice
We performed gene expression analyses on RNA from NOD,
NOD.Batf3/, and NOD.Rag1/ islets to determine whether
the block in diabetogenesis seen in the NOD.Batf3/ mice
had a unique gene expression signature. Previous studies
show that the islets of 4- to 6-week-old NOD mice had an upre-
gulation of inflammatory gene signatures enriched in interferon-
responsive genes (Carrero et al., 2013).
The typical autoreactive gene signature of the early 6-
to 8-week-old NOD mouse was absent from the islets
of NOD.Rag1/ and NOD.Batf3/ mice (Figure 4). The gene
expression differences by 6 weeks were represented as
response to stress, immune response, and antigen processing
and presentation signatures (Figures 4A and 4C). By 8 weeks
of age, statistically significant changes included inflammatory
signatures compatible with immune system process and im-
mune effector process signatures (Figures 4B and 4C). By
8 weeks of age, all major leukocyte subsets implicated in dia-
betes were represented in NOD mice (Carrero et al., 2013) but
not in the islets of NOD.Batf3/ or NOD.Rag1/ (Figure 4B).
Islets from 6-week-old NOD.Rag1/ and NOD.Batf3/mice
had virtually identical gene expression profiles. The only genes
that were more expressed in 6-week-old NOD.Rag1/ mice
when compared with NOD or NOD.Batf3/ included the Mela,
Reg3a, Reg3b, and Reg3g genes, as well as a handful of islet-
specific genes that did not fit a statistically significant grouping
(Figure 4C). These genes appear to be negatively influenced
by the systemic presence of lymphocytes in mice, an issue
that remains unresolved.
In addition to microarray analyses, we performed qRT-PCR
on cDNA from the islets of NOD and NOD.Batf3/ mice. Tran-
scripts that demonstrated inflammation of the islets, including
Cxcl9, Gbp2, Icam1, and Vcam1, were all upregulated during
the progression of diabetes (Carrero et al., 2013). These genes
were upregulated as early as 4 weeks of age in NOD but not in
NOD.Batf3/ mice (Figure 5A). T cell associated genes (Cd3e;
Figure 5A) were present starting at 4 weeks of age. No such in-
crease was found in the islets from NOD.Batf3/ mice. Coinci-
dent with T cell entry, we detected upregulation of Xcl1 and Xcr1
(Figure 5A). XCR1 is highly expressed in CD103+ DCs, while
XCL1 is produced by activated T cells (Crozat et al., 2010,
2011; Dorner et al., 2009). This likely reflects the burst of
CD103+ DCs found by flow cytometry in the experiments re-
ported in Figure 3. Furthermore, there was upregulation of Ifng
(Figure 5A) when both Cd3e and Xcl1 were upregulated, indi-
cating the activation of T cells. These findings are consistent
with our data showing the lack of increase of CD103+ DCs in con-
ditions in which anti-insulin T cells are not becoming activated or
infiltrating islets (see Figure 3). The expression of interleukin-12 isImmunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc. 661
Figure 4. Gene Expression Analysis Re-
veals a Quiescent State in NOD.Batf3–/–
Mice Islets
(A and B) Microarray analysis of the islets of NOD,
NOD.Batf3/, and NOD.Rag1/ mice. Scatter-
plots of the normalized probe intensity of all an-
notated microarray signals are shown for whole
islet preparations. Numbers labeled in red are
those that are at least 2-fold different at a 99%
confidence interval by moderated t test. Data
are plotted at a log2 scale. (A) 6 week and
(B) 8 week comparisons of NOD versus
NOD.Rag1/ (left), NOD versus NOD.Batf3/
(middle), and NOD.Batf3/ versus NOD.Rag1/
(right). Several statistically significantly different
genes are highlighted in green.
(C) Gene ontology (GO) analysis of the differentially
expressed genes between NOD and either
NOD.Rag1/ or NOD.Batf3/ at 6 or 8 weeks of
age. Corrected hypergeometric p values were
calculated using the genes selected in the scat-
terplots shown in (A) and (B). Each analysis rep-
resents the mean of three to six independent
biological replicates.
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CD103+ DCs Control Development of Type 1 Diabetesone of the important functional hallmarks of the CD103+ DC (Ma-
shayekhi et al., 2011). Il12b transcript expression was higher in
the NOD than in NOD.Batf3/ mice after 6 weeks of age (Fig-
ure 5A). We were unable to reliably detect Il12a transcripts in
our preparations (Figure 5A shows sporadic detection in 2
out of 6–9 samples per time point). Finally, we analyzed canoni-
cal markers of myeloid cells (Lyz2) and B cells (Cd19). Consistent
with our previous findings, Lyz2 (Figure 5A) andCd19 (Figure 5A)
expression increased at 8 weeks of age in NOD but not in
NOD.Batf3/ mice (Carrero et al., 2013).
Cytokine and chemokine transcript production was evaluated
by qPCR on sorted islet cells from NOD.Rag1/, NOD.Batf3/
(Figure 5B), and NOD (Figures 5C, S4A, and S4C) mice at 10–
14 weeks of age. Cells from NOD.Rag1/ mice were used to
determine chemokine patterns in an uninflamed setting when
compared to the NOD.Batf3/ mice. No major differences
were found. Purity was confirmed by gene transcript expression662 Immunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc.of Cd3e, Emr1, Ins1, and Xcr1 (Fig-
ure S4B). The CD45 component ex-
pressed Ccl2, Ccl19, Ccl21, and Ccl25
(Figure 5B). These correspond to ligands
for CCR2, CCR5, CCR7, and CCR9. The
islet macrophage expressed Ccl2, Ccl5,
Cxcl9, and Cxcl10. These correspond to
ligands for CCR1, CCR2, CCR3, CCR5,
and CXCR3. No Xcl1 transcript was
detectable (Figure 5B). Overall, this che-
mokine pattern corresponds to dendritic
cell and T cell homing.
To determine chemokine and cytokine
transcript expression in an inflamed
setting, we sorted NOD islet cells. To
ensure cleanliness, we assayed Cd3e,
Cd19, Emr1, Ins1, and Xcr1 gene tran-
scripts expressed in T cells, B cells, mac-rophages, beta cells, and CD103+ DCs, respectively, and each
gene transcript was solely expressed in the corresponding cell
lineage (Figure S4C). The most notable changes in cytokine
and chemokine patterns were the T cell production of Ifng, the
T cell production of Ccl5 and Xcl1, particularly by the CD8+ sub-
set, and the increase in production of chemokine transcripts by
the macrophage component (Ccl2 and Cxcl9) and CD45
component (Ccl19 and Cxcl10; Figure 5C).
Figure 5D shows qPCR expression of genes for retinoic acid
(RA) production: Aldh1a1 and Aldh1a2. RA production is associ-
ated with CD103+ CD11b+ DCs of the intestine, mesentery, and
lung and is linked to the conversion of T cells to the T regulatory
cell lineage (Agace and Persson, 2012; Grainger et al., 2014). The
expression of Aldh1a1 was undetectable in any of the APC pop-
ulations in the islet, while the expression of Aldh1a2 on the
CD103+ DC component was 5% of the mediastinal lymph
node DC (lung DC) positive control (Figure 5D). These data
Immunity
CD103+ DCs Control Development of Type 1 Diabetesaffirmed that the islet CD103+ DCwas not of the CD103+CD11b+
regulatory lineage.
Antigen Presentation in the Islets and the pLNs of
NOD.Batf3–/– Mice Is Reduced
To determine whether the block in diabetogenesis was due to an
absence of peptide presentation or T cell priming, we tested an-
tigen presentation with two diabetogenic CD4+ and one CD8+
T cell receptor (TCR) transgenic lines in the pLN and the islet
proper. The BDC2.5 TCR transgenic T cell (Katz et al., 1993) rec-
ognizes a beta cell antigen thought to be derived from chromog-
ranin A (Stadinski et al., 2010).The CD4+ T cell 8F10 recognizes
the insulin B chain peptide segment 12–20 (Mohan et al.,
2013). The CD8+ TCR transgenic 8.3 recognizes a peptide
from the islet-specific glucose-6-phosphatase catalytic sub-
unit-related protein (IGRP) (Lieberman et al., 2003). To determine
whether the two APCs of the islets in NOD could present diabe-
togenic peptides, we examined macrophages and CD103+ DCs
sorted from islets of NOD mice. Intraislet APCs contain peptide-
MHC complexes derived from beta cells and stimulate the
BDC2.5 T cells as well as the 8F10 T cells (Calderon et al.,
2008; Mohan et al., 2010). Both APCs presented equally to either
T cell (Figure S5A). Therewas no presentation to 8.3 (Figure S5A),
which was an expected result (Tsai et al., 2008).
Carboxyfluorescein succinimidyl ester (CFSE)-labeled spleno-
cytes from BDC2.5 TCR transgenic mice proliferated in the pLN
of NODmice, but the degree of proliferation in the NOD.Batf3/
mice was reduced to about half of that found in NOD mice (Fig-
ure 6A). A percentage of the injected T cells entered the islets of
NOD mice, where proliferation also took place (Figures 7A and
7B). However, there was no entrance of the labeled T cells into
islets of NOD.Batf3/ mice (Figure 7A). Finally, islets were iso-
lated and dispersed, and their presentation to BDC2.5 was
tested. The BDC2.5 T cell reacted equivalently to NOD and
NOD.Batf3/ dispersed islet cells (Figure 7C).
The 8F10 TCR transgenic T cell does not proliferate in the pLN,
but rather in the islets bypassing the pLN (Mohan et al., 2013).
The T cells entered and proliferated in the islets of NOD mice
but did not enter the islets of the NOD.Batf3/ mice (Figures
7D and 7E). The presentation from isolated islet cells of
NOD.Batf3/ was statistically significantly reduced when
compared to NOD (Figure 7F). We presume that presentation
came from the islet macrophages since there were no CD103+
DCs in their islets. Thus, despite the macrophages containing
the relevant peptide-MHC complexes, in the absence of the
CD103+ DC, T cell localization was impaired.
CFSE-labeled 8.3 T cells proliferated in the pLN of NOD mice,
as expected (Lieberman et al., 2003). However, there was no
proliferation in the lymph nodes of the NOD.Batf3/ mice, indi-
cating an absence in presentation of this class I peptide (Fig-
ure 6B). The 8.3 CD8+ T cells did not migrate into NOD or
NOD.Batf3/ islets (data not shown). We were only able to
detect presentation of IGRP peptides to the 8.3 hybridoma
when sorted APCs were given exogenous peptide (Figures
S5A and S5B).
The islets of the NOD.Batf3/ mice were not receptive to the
entrance of two CD4+ T cell lines despite having presentation in
the islets, albeit less efficiently in the case of the insulin epitope.
The findings with the BDC2.5 CD4+ T cells indicated that the pre-sentation in the local draining nodewas reduced.With regards to
MHC-I presentation, the NOD.Batf3/ mice showed a major
deficit in CD8+ T cell presentation and priming. These findings
support previous studies showing that cross-priming is required
in diabetes (Yamanouchi et al., 2003).
Finally, we examined the ability of T cells harvested from
diabetic NOD mice to cause diabetes in NOD.Batf3/ mice.
Spleens from diabetic NODmice contain activated diabetogenic
T cells (Wicker et al., 1986). These splenocytes were transferred
into irradiated NOD or NOD.Batf3/ mice. While about half
of recipient NOD mice developed diabetes within the first
10 days, it took 100 days for the NOD.Batf3/ mice to become
diabetic, about 10-fold longer (Figure 7G). Thus, the results
confirm that the NOD.Batf3/ islets are less receptive to
diabetogenic T cells. To determine whether NOD.Batf3/
mice had diabetogenic T cells, we transferred splenocytes into
NOD.Rag1/ recipients. After 200 days posttransfer, 40%
of the recipient NOD.Rag1/ mice became diabetic, demon-
strating that the defect in diabetogenesis in the NOD.Batf3/
mouse is not intrinsic to the lymphocytes (Figure 7H). In sum,
the lack of diabetes in NOD.Batf3/ mice is associated with
the absence of the CD103+ DC, and not with a lymphocyte
defect. We find defects in antigen presentation in islets and the
pLN with a block in the entrance of diabetogenic T cells.
DISCUSSION
This work has established the importance of the CD8a+ and
CD103+ DC lineage in the initiation of type 1 diabetes. The
absence of Batf3, and consequently this lineage, prevented the
induction and subsequent immune infiltration of islets during
diabetogenesis. Complementation of NOD.Batf3/ mice with
NOD.Rag1/ bone marrow was sufficient to reconstitute the
CD8a+ and CD103+ DC lineage and corrected the deficit. From
this and other experiments, we concluded that (1) the CD8a+
and CD103+ DC lineage was required and (2) Batf3 deficiency
had no effect on the diabetogenic capacity of lymphocytes.
Islets of NOD mice contain a population of CD103+ DCs
evident by the third to fourth week of age along with resident
macrophages, the latter representing the largest number of the
islet APCs. For these findings on CD103+ DC to be meaningful,
it was important to critically define the islet APC, as well as the
initial events at the time of the first entrance of lymphocytes. After
carefully isolating the islets, making sure to eliminate lymphoid
aggregates, only two sets of islet APCs were identified during
the critical initiation of diabetes. Cell surface markers and gene
expression analysis supported the separation of these resident
myeloid cells into these two distinct lineages.
Several crucial events in the islets characterize the initiation of
diabetes. At 3–4 weeks of age, and only in NOD mice, three
events took place: (1) an increase in the CD103+ DCs, (2) the
localization of CD4+ T cells inside islets, presumably insulin reac-
tive, and (3) changes in gene expression. Notably, the installment
of the diabetic process required two interconnected cells: the
presence of the CD103+ DCs and of CD4+ T cells that recognized
immunogenic insulin. The absence of the CD103+ DC lineage in
the NOD.Batf3/mouse resulted in a quiescent islet preventing
the autoreactive diabetic process for the life of the mouse. Islets
of NOD.Batf3/ mice were comparable with those of theImmunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc. 663
Figure 5. Real-Time PCR Shows Progression of Inflammation in NOD but Not NOD.Batf3–/– Mice Islets
(A) Taqman qRT-PCR quantification of the indicated genes. Bars represent the mean of the DCt value of the gene of interest normalized to an Actb control. All
values were adjusted by multiplying by a factor of 105 to facilitate visualization. Bars represent the mean ± SD of six biological replicates performed and tested in
duplicate. P values were calculated using Mann-Whitney U test.
(legend continued on next page)
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Figure 6. TCR Transgenic T Cells Prolifer-
ate More Effectively in the Pancreatic
Lymph Nodes of NOD than NOD.Batf3–/–
Mice
CFSE dilution of transferred (A) BDC2.5 NOD
CD4+ T cells and (B) 8.3 NODCD8+ T cells isolated
from the pancreatic lymph nodes and inguinal
lymph nodes from recipient 8- to 12-week-old
NOD or NOD.Batf3/ mice. Cells were assayed
3 days posttransfer. Dots represent individual
mice. P values were calculated using Mann-
Whitney U test (***p < 0.005).
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CD103+ DCs Control Development of Type 1 DiabetesNOD.Rag1/ mice that lacked the gene signature that charac-
terized the initiation of diabetes.
An important issue is the process whereby CD103+ DCs
localize to the islets. Previous reports show that CD8a+ and
CD103+ DCs bear the XCR1 chemokine receptor and respond
to the chemokine XCL1 (Crozat et al., 2010, 2011; Dorner
et al., 2009). Our data showed that the islet CD103+ DCs were
XCR1 positive and that XCL1 was expressed by both CD4+
andCD8+ T cells, but particularly highly by the latter. It is possible
that the expression of Xcl1 resulted in the increase in the CD103+
DCs. However, no Xcl1 was detectable in islets of mice that
expressed the baseline number of CD103+ DCs, such as in
NOD.Rag1/ mice. Analysis of NOD.Rag1/ islet demon-
strated the production of transcripts for chemoattractants
responsible for DC and T cell homing. Previous studies show
that these transcripts are specific to the pancreas of NOD and
are not in other strains of mice (Bouma et al., 2005). However,
their role remains unresolved. Expression of chemokine tran-
scripts was low, and, despite their presence, the islets of the
NOD.Batf3/ mice lacked DC or lymphocytes, suggesting a
nonchemokine-driven process that drives early lymphoid and
myeloid entry into islets.
Our data suggest that there are two processes that are influ-
enced by the CD103+ DCs. The first centers on early T cell local-(B–D) The indicated populations were sorted from (B) NOD.Rag1/ andNOD.Batf3/ as shown previously, (C
CD11c+ MHC-II+ cells from mediastinal lymph nodes. Taqman or SYBR Green I qRT-PCR was used to quant
SD of two biological replicates performed and tested in duplicate.
See also Figure S4.
Immunity 41, 657–669,ization to islets. Because there is an
absence of T cells in the islets of the
NOD.B16A mice, the anti-insulin CD4+
T cells are likely the initiating autoimmune
T cells. These anti-insulin CD4+ T cells
enter islets of NOD mice in the absence
of the pLN (Mohan et al., 2013) but were
not found in the NOD.Batf3/ mice.
The lack of entrance was confirmed
in the experiments transferring CFSE-
labeled anti-insulin CD4+ T cells into
the NOD.Batf3/ mice. The absence of
T cells in islets from NOD.Batf3/ mice
occurred despite the presentation of dia-
betic peptides by the resident macro-
phages and the presence of diabetogenicT cells in the spleen. Thus, the CD103+ DC is essential for
entrance of anti-insulin CD4+ T cells that initiate diabetogenesis.
The CD103+ DCmay be necessary for the islet to be receptive to
T cell entrance through ways that we are now investigating.
The second process influenced by the CD103+ DCs is the
priming of CD8+ T cells in the pLN. An absence of presentation
of class I MHC epitopes in the NOD.Batf3/ mice was evident
in the draining pLN, as determined by transferring IGRP CD8+
reactive T cells. Therefore, the absence of CD103+ DC also re-
sults in the ablation of the CD8+ T cell response, which consti-
tutes the effector T cell in diabetes. The involvement of CD8+
T cell in NOD autoimmunity has been recognized since early
studies in which spleen cells transferred diabetes into nondia-
betic NOD mice, although these required the presence of both
CD4+ and CD8+ T cells. The requirement of CD8+ T cells was
also noted in mice lacking beta 2-microglobulin and in studies
showing that CD8+ T cells directed to beta cell antigens can
participate in the diabetic process (de Jersey et al., 2007; Kay
et al., 1996; Serreze et al., 1994, 2004; Wang et al., 1996; Wicker
et al., 1994). We posit that the CD103+ DC is the essential APC
for diabetogenic class I MHC epitopes. This is based on the
strong findings showing that the CD8+ TCR transgenic T cell rec-
ognizes a peptide of IGRP. Therewas no presentation in the pLN,
a site thought to be crucial for the selection and activation ofand D) NODmouse islets as in Figure S4A, and (D)
ify the indicated genes. Bars represent the mean ±
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Figure 7. TCR Transgenic T Cell Entrance into NOD or NOD.Batf3–/– Islets and Splenocyte Transfer into Recipients
(A–F) (A) Percentage entering islets and (B) CFSE dilution of CD45.1+ and CD45.2+ BDC2.5 NODCD4+ T cells (both at day 3 posttransfer). (D) Percentage entering
islets and (E) CFSE dilution of CD45.1+ and CD45.2+ 8F10 NOD CD4+ T cells transferred into 6- to 12-week-old NOD or NOD.Batf3/ mice (both at day 7
posttransfer). Dispersed islet cell presentation to (C) BDC2.5 hybridoma and (F) 8F10 hybridoma wasmeasured by CTLL-2 assay for IL-2. Each dot represents an
independent T cell assay. Representative flow cytometry plots and cumulative data from two or more independent experiments are shown. P values were
calculated using Mann-Whitney U test (**p < 0.005).
(G) Diabetic NOD splenic T cells were isolated using CD90.2 magnetic beads, and then 107 cells were transferred to the indicated irradiated (600 cGy) recipients.
(H) 10- to 12-week-old NOD or NOD.Batf3/ splenocytes (107) were transferred into NOD.Rag1/ recipients. Recipient mice in (G) and (H) were then monitored
for diabetes. Diabetes incidence was monitored as indicated in the Experimental Procedures.
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2002).
In summary, these data allow us to posit a model for the initi-
ating events of the autoreactive process in islets of Langerhans.
The first set of CD4+ T cells that enter islets are the insulin-reac-
tive T cells, those akin to the 8F10 TCR transgenic mouse (Mo-
han et al., 2013). These T cells initiate the autoimmune process,
enter islets spontaneously without the need for priming in the
pLN, and require both the display of immunogenic insulin and
the presence of CD103+ DC (e.g., the findings in the NOD.B16A
and NOD.Batf3/ mice; Mohan et al., 2013; Nakayama et al.,
2005). Once insulin reactive T cells encounter CD103+ DC, an
amplification loop begins: a burst of CD103+ DCs enters islets,
antigen presentation increases in the pLN, additional inflamma-
tory cells enter islets, and, importantly, the autoreactive CD8+
T cells are primed. This scenario takes place starting at about666 Immunity 41, 657–669, October 16, 2014 ª2014 Elsevier Inc.the fourth week of life and increases very rapidly during a limited
time period, after which the diabetogenic process is in full oper-
ation and difficult to control. The pLNs are not required beyond
3 weeks of age, as their removal does not halt the diabetic pro-
cess (Gagnerault et al., 2002). This working scenario sets the
base for future investigations.EXPERIMENTAL PROCEDURES
Mice
NOD/ShiLtJ (NOD), NOD.129S7(B6)-Rag1tm1Mom/J (NOD.Rag1/), NOD.Cg-
Tg(Ins2*Y16A)1EllIns1tm1JjaIns2tm1Jja/GseJ (NOD.B16A), NOD.Cg-H2h4/
DilTacUmmJ (NOD.h4), NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ
(BDC 2.5), and NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ (8.3) mice were ob-
tained from the Jackson Laboratory. NOD.Batf3/ mice were generated by
breeding the 129S-Batf3tm1Kmm/J mouse obtained from Dr. Kenneth
Murphy to NOD. Speed congenics was utilized, selecting for the highest
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CD103+ DCs Control Development of Type 1 Diabetespercentage of NOD microsatellite markers at each generation resulting in
100% NOD microsatellite markers at the sixth generation of backcross. SNP
analysis by the Jackson Laboratory confirmed that the IDD loci were of the
NOD background. NOD.Batf3/ 3 Rag1/ were generated by intercrossing
NOD.Batf3/ with NOD.129S7(B6)-Rag1tm1Mom/J. The donor bone marrow
cells used for reconstitution were obtained from NOD.Rag1/ and
NOD.Batf3/ 3 Rag1/ mice. The donor mice had been administered
150 mg/kg 5-fluorouracil (Sigma-Aldrich) prior to harvesting the bone marrow.
The bone marrow was harvested 5 days post 5-fluorouracil injection and
transferred intravenously into 300 cGY-treated 3-week-old NOD.Batf3/
recipients. All mouse experiments were approved by the Division of Compar-
ative Medicine of Washington University School of Medicine (Association for
Assessment and Accreditation of Laboratory Animal Care [AAALAC] accredi-
tation number A3381-01).
Histology and Islet Isolation
Pancreata were sectioned and stained by conventional techniques. For islet
isolation, the pancreata were perfused (5 ml Hank’s balanced salt solution
without calcium supplemented with collagenase), removed, and digested in
a 37C water bath for 15 min. After being shaken for 90 s, the pancreata
were washed three times and passed through a 70 mm filter. The remains
were flushed from the filter, and islets were handpicked using the zinc-
chelating dye dithizone (Sigma-Aldrich; 200 mg/mL 10% DMSO PBS) as a
marker of islets.
Flow Cytometry and Cell Sorting
Flow cytometry was performed using a FACSCanto II (BD Biosciences), and
data were analyzed using FlowJo software (Tree Star Software). See Supple-
mental Experimental Procedures for complete antibody list. Islets were har-
vested as described previously and dispersed via Cell Dissociation Solution
Non-Enzymatic (Sigma-Aldrich) for 5 min at 37C. Single-cell suspensions
were treated with 2.4G2 conditioned media (PBS, 1% bovine serum albumin,
and 50% 2.4G2 in Dulbecco’s modified Eagle’s medium [DMEM]) at 4C for
15 min to block FC receptors. Cells were then stained with fluorescent anti-
bodies and sorted via FACSAria II (BD Biosciences).
Diabetes Monitoring
Blood glucose was monitored daily or weekly; after two consecutive readings
of R250 mg/dL, mice were considered diabetic (Chemstrip 2GP, Roche
Diagnostics).
RNA Isolation, Real-Time PCR, and Microarray Analysis
RNA isolation and qRT-PCRwere performed as in Carrero et al. (2013) with mi-
nor modifications (see Supplemental Experimental Procedures). RNA (50 ng)
was amplified using Ovation PicoSL WTA System V2 (NuGEN) following the
manufacturer’s instructions. Amplified RNA (100 ng) was labeled using Affy-
metrix GeneChip Whole Transcript Sense Target Labeling Assay following
the manufacturer’s instructions (Affymetrix). Labeled RNA was hybridized
to Mouse Gene 1.0 ST microarrays using a GeneChip Fluidics Station 450
(Affymetrix). Microarrays were scanned using a GeneChip Scanner 3000 7G
(Affymetrix). All GeneChip processing steps were performed by the Laboratory
for Clinical Genomics at Washington University School of Medicine.
In Vivo T Cell Proliferation and Antigen Presentation Assays
8F10, BDC2.5, and 8.3 TCR transgenic mouse spleens were harvested and
dispersed into single-cell suspensions. CD4- or CD8-positive cells were
selected via magnetic microbead cell separation (Miltenyi Biotech) according
to the manufacturer’s protocol. The cells were then stained with 1 mM carbox-
yfluorescein diacetate succinimidyl ester (CFDA SE) (Life Technologies) for
15 min at 37C and immediately quenched with 4C DMEM supplemented
with 10% fetal calf serum. Cells (5–10 3 106) were transferred via intravenous
injection into recipient mice. After 3–7 days, islets, draining pancreatic lymph
nodes, and inguinal lymph nodes were harvested, dispersed into single-cell
populations, and stained with fluorescent antibodies. Flow cytometry was per-
formed and analyzed as described above. For antigen presentation assays,
T cell hybridomas (5 3 104 per well) were cultured with dispersed islet cells
(5 3 104 per well) and with peptide-pulsed APC (5 3 104 or 5 3 105 per well)
as controls. After incubating for 18 hr, the culture supernatant of each wellwas assayed for IL-2 production through use of the IL-2-dependent cell line
CTLL-2. Proliferation of CTLL-2 was assessed by [3H] thymidine incorporation.
Statistical Analysis
Mann-Whitney U test was used to determine significant differences between
samples. All data were plotted using GraphPad Prism 6 (GraphPad Software).
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